https://vitalspanwire.com/news/efgartigimod-phase-3-autoimmune-myositis-alkiviaVitalspan Wireen2026-08-18T21:03:39.681ZArgenx reports Phase 3 efgartigimod benefit in autoimmune myositishttps://vitalspanwire.com/news/fda-competency-reviews-generative-ai-medical-devicesVitalspan Wireen2026-08-18T16:01:55.880ZFDA explores competency-based reviews for generative-AI medical deviceshttps://vitalspanwire.com/news/timp2-aging-brain-microglia-miceVitalspan Wireen2026-08-18T14:04:11.198ZTIMP2 shifts aging brain immune cells toward improved debris handling in micehttps://vitalspanwire.com/news/dti-alps-alzheimers-biomarkers-adniVitalspan Wireen2026-08-18T13:58:23.737ZMRI fluid-dynamics measure tracks Alzheimer’s biomarkers in ADNI analysishttps://vitalspanwire.com/news/plasma-glycine-biological-aging-uk-biobankVitalspan Wireen2026-08-18T13:58:23.679ZHigher plasma glycine tracks with a younger biomarker profile—not slower aginghttps://vitalspanwire.com/news/lilly-retatrutide-seller-lawsuitsVitalspan Wireen2026-08-18T13:58:23.605ZLilly files six lawsuits targeting sellers of unapproved retatrutide